Healthcare provider profile · identity verified

Anu Mittal, D.O.

Internal Medicine · LOMA LINDA, CA · NPI 1497933634

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	572	229
Amlodipine Besylate	Amlodipine Besylate	493	208
Losartan Potassium	Losartan Potassium	331	138
Levothyroxine Sodium	Levothyroxine Sodium	291	104
Lisinopril	Lisinopril	278	119
Rosuvastatin Calcium	Rosuvastatin Calcium	238	91
Gabapentin	Gabapentin	212	83
Metformin Hcl	Metformin Hcl	169	76
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	167	63
Omeprazole	Omeprazole	149	67
Metoprolol Tartrate	Metoprolol Tartrate	145	49
Ibuprofen	Ibuprofen	122	55
Potassium Chloride	Potassium Chloride	120	53
Metformin Hcl Er	Metformin Hcl	119	53
Pantoprazole Sodium	Pantoprazole Sodium	119	48
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	116	44
Bisoprolol Fumarate	Bisoprolol Fumarate	112	45
Simvastatin	Simvastatin	112	44
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	106	50
Hydrochlorothiazide	Hydrochlorothiazide	102	47
Alendronate Sodium	Alendronate Sodium	99	41
Tramadol Hcl	Tramadol Hcl	95	33
Ozempic	Semaglutide	94	15
Atenolol	Atenolol	93	43
Pradaxa	Dabigatran Etexilate Mesylate	92	27
Meloxicam	Meloxicam	88	41
Albuterol Sulfate Hfa	Albuterol Sulfate	83	62
Jardiance	Empagliflozin	81	36
Furosemide	Furosemide	79	37
Trazodone Hcl	Trazodone Hcl	74	28
Hydralazine Hcl	Hydralazine Hcl	72	28
Glipizide	Glipizide	71	30
Terazosin Hcl	Terazosin Hcl	69	24
Carvedilol	Carvedilol	65	23
Azelastine Hcl	Azelastine Hcl	63	17
Humulin N	Insulin Nph Human Isophane	61	22
Escitalopram Oxalate	Escitalopram Oxalate	60	22
Montelukast Sodium	Montelukast Sodium	60	28
Spironolactone	Spironolactone	59	21
Glipizide Er	Glipizide	56	22
Prednisone	Prednisone	52	42
Tamsulosin Hcl	Tamsulosin Hcl	52	28
Famotidine	Famotidine	51	23
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	49	16
Humulin N Kwikpen	Insulin Nph Human Isophane	48	18
Triamcinolone Acetonide	Triamcinolone Acetonide	48	24
Acetaminophen-Codeine	Acetaminophen With Codeine	44	suppressed
Cephalexin	Cephalexin	44	39
Oxybutynin Chloride Er	Oxybutynin Chloride	42	15
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	42	12
Victoza 2-Pak	Liraglutide	42	11
Ezetimibe	Ezetimibe	41	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	41	21
Risedronate Sodium	Risedronate Sodium	38	11
Wixela Inhub	Fluticasone Propion/Salmeterol	37	17
Baclofen	Baclofen	36	15
Duloxetine Hcl	Duloxetine Hcl	36	13
Buspirone Hcl	Buspirone Hcl	35	suppressed
Clopidogrel	Clopidogrel Bisulfate	35	15
Acyclovir	Acyclovir	34	17
Fluticasone Propionate	Fluticasone Propionate	34	13
Ciprofloxacin Hcl	Ciprofloxacin Hcl	33	32
Sertraline Hcl	Sertraline Hcl	32	16
Lovastatin	Lovastatin	29	11
Liraglutide	Liraglutide	28	13
Allopurinol	Allopurinol	27	11
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	27	11
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	26	suppressed
Bupropion Hcl Sr	Bupropion Hcl	25	suppressed
Lidocaine	Lidocaine	25	suppressed
Eliquis	Apixaban	24	suppressed
Estradiol	Estradiol	23	14
Humulin R	Insulin Regular, Human	23	11
Doxycycline Monohydrate	Doxycycline Monohydrate	22	22
Hydroxyzine Hcl	Hydroxyzine Hcl	22	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	22	suppressed
Nitroglycerin	Nitroglycerin	22	13
Nortriptyline Hcl	Nortriptyline Hcl	22	suppressed
Propranolol Hcl	Propranolol Hcl	22	suppressed
Nifedipine Er	Nifedipine	21	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	21	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	20	20
Arexvy	Rsvpref3 Antigen/As01e/Pf	20	20
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Lorazepam	Lorazepam	20	11
Naproxen	Naproxen	20	suppressed
Ondansetron Odt	Ondansetron	20	suppressed
Terbinafine Hcl	Terbinafine Hcl	20	suppressed
Victoza 3-Pak	Liraglutide	20	suppressed
Amoxicillin	Amoxicillin	19	17
Morphine Sulfate Er	Morphine Sulfate	19	suppressed
Nystatin	Nystatin	19	12
Topiramate	Topiramate	19	suppressed
Alprazolam	Alprazolam	18	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	18	suppressed
Finasteride	Finasteride	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Clonidine Hcl	Clonidine Hcl	17	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Lactulose	Lactulose	17	suppressed
Cefuroxime	Cefuroxime Axetil	16	15
Clobetasol Propionate	Clobetasol Propionate	16	suppressed
Metronidazole	Metronidazole	16	12
Humalog	Insulin Lispro	15	suppressed
Mupirocin	Mupirocin	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Spiriva Respimat	Tiotropium Bromide	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Clonazepam	Clonazepam	14	suppressed
Ondansetron Hcl	Ondansetron Hcl	14	12
Pravastatin Sodium	Pravastatin Sodium	14	suppressed
Temazepam	Temazepam	14	suppressed
Methenamine Hippurate	Methenamine Hippurate	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Alvesco	Ciclesonide	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Trospium Chloride	Trospium Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error